ChemoTech is an international medical technology company based in Lund owned by Neem’s Hill AB, Sweden, founded in 2015 by a team with expertise in radiation physics, surgical oncology and clinical development.
The R&D strategy emerged from the mother company’s recognition, that many adverse effects associated with traditional electrochemotherapy can be related to destructive effects on treated tissue. This understanding led to the development of Tumour Specific Electroporation™ (TSE), with the objective of achieving effective tumour treatment while limiting unnecessary damage to surrounding healthy tissue.
Leveraging extensive experience in medical technology, clinical applications and commercialisation, ChemoTech focuses on developing innovative and less destructive treatment technologies for human cancer care.
Neems Hill’s technology platform, Tumour Specific Electroporation™ (TSE), is designed to enhance the uptake of therapeutic molecules in cancerous tissue through controlled electrical stimulation. The technology is intended to increase the local effect of anti-cancer drugs while reducing unnecessary destruction of surrounding healthy tissue.
TSE automatically adapts energy delivery to the electrical characteristics of the treated tissue, supporting a controlled and tumour-specific treatment approach.
Our vision & mission
Our mission
Our mission is to advance cancer care by developing innovative treatment technologies for patients with limited therapeutic alternatives. Through focused research, development and efficient production, we aim to make TSE accessible in markets where the medical need is significant and existing treatment options may be insufficient.
Our vision
Our strategy is to establish TSE and IQwave™ in selected international oncology markets while continuing the clinical and technological development of the platform for new applications in human cancer care.
The development of TSE stems from the founders’ extensive expertise in oncology, surgery, and international business development. Unlike traditional approaches that aim to destroy cancer cells rapidly, we explored how to achieve controlled tumour cell death, improving the treatment process and outcomes.
Research and clinical studies have shown that many ablation techniques are effective only for small tumours (under 2–3 cm). Larger tumours often respond poorly to these treatments. By addressing these limitations, TSE offers a breakthrough in treating larger and more complex tumours, providing a better chance for successful outcomes.
We observed that ablation techniques in oncology shared similar limitations. In published studies, it was further demonstrated that good treatment results had a clear correlation with small tumours under 2–3 centimetres. When treating larger tumours, the treatment results were significantly worse, and a correlation between a good treatment result and the patient’s tumour size could be established.
Get in touch
Are you interested in our products?
Our team is here to help with any questions about our products, patents or anything else you may need help with.
This website uses cookies. If you continue to browse the website, you agree to the use of cookies.